Innovation in the use, design and regulation
of nicotine delivery medicines4.31 The Medicines and Healthcare products
Regulatory Agency (MHRA) regulates nicotine
delivery medicines, and so will invite applications
for licences to cover the new routes to quitting.
4.32 Nearly a fifth of smokers use NRT, bought
from a retail outlet, to assist their quit attempt
by cutting down in certain situations. However,
feedback from smokers suggests that NRT is
not easily accessible (unlike tobacco) and can
be expensive (which introduces a disincentive to
use it).16
4.33 The MHRA will encourage manufacturers
to develop and market new and improved
products. At the same time, the Government
will work with the pharmaceutical industry
and retailers to encourage the development
of improved pack information, guidance and
training packages for retailers on the use of
nicotine delivery medicines, so that smokers
can be better informed and retailers feel more
confident in talking to their customers about the
products.
4.34 The Government will also work with the
pharmaceutical industry and other partners to
dispel the myths surrounding the harms from
nicotine. While it is the nicotine within the
tobacco that the smoker craves and is addicted
to, it is the tar and the carbon monoxide in
smoked tobacco that are the causes of smoking related
disease and death.
4.35 We believe that these actions will
encourage innovation in the use, design and
marketing of nicotine delivery medicines.
However, over the past year, we have already
seen the emergence of many different forms of
nicotine delivery systems, including e-cigarettes
and nicotine hand gels. These products
are unregulated and their safety remains
undetermined.
4.36 Given the pharmacological action of
nicotine, the Government will create a level
playing field by regulating all products that
contain nicotine (apart from tobacco, which is
regulated by specific tobacco legislation) under
medicines safety legislation. This will mean that
any producer of a nicotine-containing product
or nicotine delivery medicine will need to meet
certain requirements for safety, quality and
efficacy, in order to protect the public. The first
step towards the creation of this new regulatory
scheme for nicotine-containing products will be
a public consultation, to be undertaken by the
MHRA and launched alongside this strategy.
4.37 The Government will ensure that no
nicotine-containing products or nicotine delivery
medicines can be marketed in a way that
promotes or encourages tobacco use. We will also
keep nicotine delivery medicines under review.
In particular, we will monitor the impact of the
medicines’ availability on quit rates at a national
level, the safety implications of long-term use of
the medicines and the potential for their abuse....
For a fuller story, keep your eyes peeled on this thread;
http://vapersnetwork.org/forum/showthread.php?tid=166I cannot think of any words constructive or otherwise at the moment
